MedTrace Logo

Docosahexaenoic Acid (DHA) Administration and Length of Gestation: a Feasibility Study

NCT00691418 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2015-03-06

No results posted yet for this study

Summary

This is a feasibility study to determine if it will be possible to conduct a larger study of the effect of docosahexaenoic acid (DHA), an omega fatty acid, on increased length of gestation among women who have had a previous preterm delivery.

Conditions

  • Premature Birth

Interventions

DIETARY_SUPPLEMENT

docosahexaenoic acid (DHA)

600 mg per day of docosahexaenoic acid (DHA) starting at 22-24 weeks gestation until delivery.

DIETARY_SUPPLEMENT

placebo

placebo once per day starting at 22-24 weeks gestation until delivery.

Sponsors & Collaborators

  • DSM Nutritional Products, Inc.

    collaborator INDUSTRY

  • Kaiser Permanente

    lead OTHER

Principal Investigators

  • Gabriel Escobar, MD · Kaiser Permanente

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-08-31
Completion
2009-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00691418 on ClinicalTrials.gov